PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma

Background Molecular biomarkers assisting risk-group assignment and subsequent treatment stratification are urgently needed for patients with squamous cell cancer of the head and neck region (HNSCC). Aberrant methylation is a frequent event in cancer and, therefore, a promising source for potential biomarkers. Here, the methylation status of the paired-like homeodomain transcription factor 3 (PITX3) was evaluated in HNSCC. Methods Using a quantitative real-time PCR, PITX3 methylation was assessed in a cohort of 326 HNSCC patients treated for localized or locally advanced disease (training cohort). The results were validated with Infinium HumanMethylation450 BeadChip data from a 528 HNSCC patient cohort (validation cohort) generated by The Cancer Genome Atlas (TCGA) Research Network. Results PITX3 methylation was significantly higher methylated in tumor compared to normal adjacent tissue (NAT; training cohort: median methylation NAT 32.3%, tumor 71.8%, p < 0.001; validation cohort: median methylation NAT 16.9%, tumor 35.9%, p < 0.001). PITX3 methylation was also significantly correlated with lymph node status both in the training (p = 0.006) and validation (p < 0.001) cohort. PITX3 methylation was significantly higher in HPV-associated (p16-positive) tumors compared to p16-negative tumors (training cohort: 73.7 vs. 66.2%, p = 0.013; validation cohort: 40.0 vs. 33.1%, p = 0.015). Hypermethylation was significantly associated with the risk of death (training cohort: hazard ratio (HR) = 1.80, [95% confidence interval (CI) 1.20–2.69], p = 0.005; validation cohort: HR = 1.43, [95% CI 1.05–1.95], p = 0.022). In multivariate Cox analyses, PITX3 added independent prognostic information. Messenger RNA (mRNA) expression analysis revealed an inverse correlation with PITX3 methylation in the TCGA cohort. Conclusions PITX3 DNA methylation is an independent prognostic biomarker for overall survival in patients with HNSCC and might aid in the process of risk stratification for individualized treatment.


Background
With an estimated incidence of more than 60,000 cases in the USA alone, cancer of the head and neck region is a common malignant disease. In male patients, cancer of the oral cavity and pharynx is the eighth most common cancer type. For 2016, 13,190 patients are estimated to succumb to the disease [1]. The most prevalent histological subtype in the head and neck region is squamous cell carcinoma (HNSCC), and common risk factors are the concurrent abuse of tobacco and alcohol as well as infections with a high-risk human papillomavirus (HPV) like HPV16 and HPV18. Depending on the causative agent, distinct differences have been recorded with regard to molecular alterations, tumor site, and prognosis of the tumors. While TP53 mutations are the most common alterations in smoking-related cancers, HPV-associated tumors predominantly harbor PIK3CA mutations [2]. Moreover, patients with HPV-associated tumors tend to be younger, and tumors are more likely to develop in the oropharynx. Notably, these patients also have a better overall survival [3].
Most patients present in an advanced stage of disease. Surgery or radiation therapy with concurrent chemotherapy are first-line treatment options for HNSCC patients, but local and distant failure is common [4]. Newer drugs like the anti-EGFR antibody cetuximab have been successfully implemented into the therapeutic portfolio of HNSCC [5]. Combined with standard platinum-based chemotherapy, they provide a significant overall survival benefit for patients with recurrent or metastatic disease. For the same patient group, immunotherapy agents like the immune checkpoint inhibitor pembrolizumab have recently shown high efficacy [6]. Based on these results, pembrolizumab has recently been approved by the US Food and Drug Administration (FDA) for patients with recurrent or metastatic HNSCC. Considering the dismal prognosis in the event of metastatic or recurrent disease, such advances in drug therapy are urgently needed [7].
As yet, no prognostic molecular biomarkers have been established to assist clinicians in stratifying treatment or surveillance options after initial curative treatment. Currently, clinicopathological parameters like lymph node metastasis or tumor stage serve to identify high-risk patients. Additional biomarkers would be of utmost value to influence treatment strategy and surveillance intensity. With regard to emerging immunotherapy options that have an improved safety and side-effect profile, molecular biomarkers could distinguish patient subgroups that would benefit from adjuvant or neoadjuvant therapy. These biomarkers could further be evaluated in conjunction with other newly identified adverse risk factors like delayed time to treatment [8].
Tissue-based biomarkers have already been established for other tumor entities. In breast carcinoma, the commercially available multi-gene panel assay Oncotype DX © estimates risk of recurrence after first-line treatment for early stage breast cancer by analyzing the expression of 21 genes [9]. Patients who have been identified as high risk based according to the subsequently calculated recurrence score may profit from intensified surveillance or adjuvant chemotherapy. Another promising biomarker approach is the investigation of the methylation status in a tumor sample. Epigenetic regulation is conferred through methylation, and malignant tumors are frequently hyper-or hypomethylated. Depending on the locus, methylation can result in gene transcription or repression [10]. Methylation analysis has already changed clinical practice for glioblastoma treatment, where promoter methylation of MGMT is predictive of response to the drug temozolomide [11]. So far, this is the only clinically implemented DNA methylation-based predictive biomarker test. DNA methylation can be quantified reliably and reproducibly via microarray, sequencing, or real-time PCR after bisulfite conversion of DNA [12][13][14]. Moreover, due to the stability of DNA methylation, the methylation status can be easily obtained even from degraded material like formalin-fixed paraffin-embedded (FFPE) tissue [15], which represents the most common clinically relevant sample material. Thus, studying epigenetic alterations is a promising approach for the development of biomarkers. Several epigenetic biomarkers have been tested in HNSCC, sometimes with conflicting results [16]. Hypermethylation of TIMP3 and CCNA1, for instance, have been associated with an increased risk of developing second primary tumors [17]. Hypermethylation of a gene panel in salivary samples prior to treatment was shown to be prognostic of local recurrence and overall survival [18]. Consequently, epigenetic markers are emerging as prognostic tools in patients with HNSCC.
The paired-like homeodomain transcription factor 3 (PITX3), located on chromosome 10q24 [19], plays an important role in the midbrain dopamine system development, and single-nucleotide polymorphisms within the PITX3 gene have been associated with Parkinson's disease [20]. While the role of PITX3 in the brain development has been well characterized, its contribution to tumorigenesis remains more elusive. It has been found to be hypermethylated in breast cancer tumors [21]. Recently, Holmes et al. reported that PITX3 promoter methylation is strongly associated with biochemical recurrence-free survival in prostate cancer patients [22].
PITX3 shares a sequence similarity and at least partly redundant function with the paired-like homeodomain 2 (PITX2) [21,23]. PITX2 promoter methylation is a well studied prognostic biomarker in various cancers, i.e. prostate, breast, and biliary tract cancers [24][25][26][27][28][29][30][31]. Recent studies investigating the methylation status of PITX2 in HNSCC and lung cancer cohorts found that hypermethylation was associated with improved survival [32,33]. An in vitro diagnostic (IVD) test for anthracycline sensitivity in breast cancer patients based on PITX2 methylation is currently being developed for commercial distribution by the company Therawis GmbH (Munich, Germany). Similar to PITX2, the closely related transcription factor PITX1 plays a role in the embryonal development [34]. PITX1 has been found to be predictive of chemosensitivity in a small HNSCC cohort [35].
Given the need for new prognostic biomarkers for patients with curatively treated HNSCC and the promising results regarding PITX2 methylation as a biomarker, the methylation status of PITX3 was investigated in wellannotated HNSCC cohorts.

Patients and ethics
The training cohort comprised 326 retrospectively enrolled HNSCC patients treated at the University Hospital Bonn. Clinical data were obtained for the majority of patients. The study was approved by the Institutional Review Board of the University Hospital Bonn, which waived the need for written informed consent. The validation cohort consisted of 528 HNSCC patients analyzed by The Cancer Genome Atlas (TCGA) Research Network (http://cancergenome. nih.gov/). All experiments were conducted in accordance with the Helsinki Declaration of 1975.

Sample preparation, DNA extraction, and bisulfite conversion
Freshly cut sections from FFPE blocks were stained with hematoxylin and eosin. The tumor area was annotated and macrodissected from unstained slides for subsequent methylation analysis. The process of DNA extraction and bisulfite conversion was performed using the innuCONVERT Bisulfite All-In-One Kit (Analytik Jena, Germany) as previously reported [36]. In order to assess HPV status, the surrogate marker p16 was evaluated by immunohistochemistry.
DNA and messenger RNA (mRNA) from samples from the validation cohort were prepared as described by the TCGA Research Network (www.cancergenome.nih.gov).

PITX3 quantitative methylation analysis
For the training cohort, quantitative PITX3 methylation analysis was performed by means of quantitative realtime PCR (qPCR) with primers and probes as previously described [22]. The analytical performance of the qPCR assay has been characterized earlier [22].
For the validation cohort, DNA methylation data were generated by the TCGA Research Network using the Infinium HumanMethylation450 BeadChip (Illumina, Inc., San Diego, CA, USA). HumanMethylation450 data of level 2 were downloaded directly from the TCGA webpage. The data files included background-corrected methylated (bead_M) and unmethylated (bead_U) bead pair summary intensities as extracted by the R package 'methylumi'. The bead pair (cg20023259) in proximity to the locus of the qPCR assay was selected. Methylation values for the bead pair were calculated by the formula 100% × bead_M/(bead_M + bead_U). The position of the qPCR assay and the bead pair cg20023259 within the PITX3 gene is shown in Fig. 1.

PITX3 mRNA expression analysis
The PITX3 mRNA data obtained from the TCGA Research Network were generated by means of the Illumina HiSeq 2000 RNA Sequencing version 2 analysis (Illumina, Inc., San Diego, CA, USA) as described by the TCGA Research Network (www.cancergenome.nih.gov). PITX3 mRNA expression (normalized counts) data of level 3 were downloaded from the TCGA webpage.

Statistical analysis
Statistical analyses were performed using SPSS, version 24 (SPSS Inc., Chicago, IL, USA). Bivariate correlations were tested using the Spearman rank correlation coefficient (ρ). Overall survival analyses were conducted by Kaplan-Meier and Cox proportional hazards regression analyses. The Mann-Whitney U test and one-way analysis of variance (one-way ANOVA) were employed for the comparison of groups. p values <0.05 were considered significant.

PITX3 DNA methylation and mRNA expression in HNSCC tissue
The results from the validation cohort are entirely based upon data generated by the TCGA Research Network. The PITX3 locus was highly methylated in tumor tissues from the training and the validation cohort. Histograms of PITX3 methylation frequencies in both cohorts are shown in Fig. 2a, c. In the training cohort, methylation data were available for 466 patient samples including 140 normal and 326 tumor tissue samples. The comparison of PITX3 methylation in tumor and normal adjacent tissue (NAT) revealed a significant difference between tumor tissue (mean 69.0%, median 71.8%) and NAT (mean 32.1%, median 32.3%; p < 0.001; Fig. 2b). Methylation ranged from 0.79 to 100% in tumor tissue and from 0 to 82.1% in normal tissue. This finding was confirmed in the validation cohort, in which methylation data were available for 578 patient samples including 50 normal and 528 tumor tissue samples. Methylation was significantly different between tissue types (p < 0.001; Fig. 2d) and ranged from 6.9 to 76.3% in tumor tissue (mean 36.5%, median 35.9%) and from 11.7 to 26.1% in normal tissue (mean 17.1%, median 16.9%). The methylation differences observed between the two analyzed cohorts might be caused by   the application of two different technologies: qPCR and Infinium HumanMethylation450K BeadChip. Furthermore, DNA methylation was shown to be inversely correlated with PITX3 mRNA (p = 0.036) in the validation cohort. Interestingly, mRNA levels were also significantly different in tumor (mean 6.55 normalized counts) compared to normal (mean 15.37 normalized counts) tissue (p < 0.001).

Association of PITX3 DNA methylation with clinico-pathological parameters
Both in the training and validation cohort, PITX3 DNA methylation was significantly associated with lymph node status (p = 0.006 and p < 0.001, respectively). Moreover, a significant methylation difference was found in regard to HPV status in the training cohort. Using p16 as surrogate marker, p16-negative tumors were significantly lower methylated than p16-positive tumors (66.2 vs. 73.7%, p = 0.018). This was confirmed in the validation cohort: HPV-associated (p16-positive) tumors were significantly highly methylated than p16-negative tumors (40.0 vs. 33.1%, p = 0.015). In addition, a significant difference in methylation was found when analyzing tumor site in both cohorts (training cohort: p = 0.023, validation cohort: p = 0.017). A detailed analysis of both cohorts can be found in Table 1.

Discussion and conclusions
Squamous cell cancer of the head and neck region poses a substantial global health burden and affects patients with a history of nicotine and alcohol abuse as well as patients harboring oral infections with high-risk HPV. The disease poses a large health burden worldwide. Surgery and radiotherapy are the mainstay of therapy with curative intent. Recent advantages in reconstructive techniques may help to reduce morbidity after extensive surgery of radiation-induced damage [37][38][39]. For patients undergoing curative therapy, biomarkers are urgently needed to identify individuals who are likely to experience tumor recurrence or metastasis and subsequent diseaserelated death. These patients could benefit from intensified surveillance or adjuvant therapy. Moreover, new immunotherapeutic drugs are emerging from which high-risk patients might benefit.
Epigenetic alterations in form of hypo-or hypermethylated DNA are frequent events in cancer. Investigating the DNA methylation status in patients with malignant  b Training cohort (p16-negative patients). c Validation cohort (all patients). High PITX3 DNA methylation was associated with an adverse prognosis in both cohorts, in particular in p16-negative patients from the training cohort. A subgroup analysis of p16-negative patients from the validation cohort was not performed due to largely missing data diseases is a promising approach to establish new biomarkers. In the present study, PITX3 DNA methylation was analyzed in a well-annotated HNSCC cohort from the University Hospital Bonn. In multivariate analysis, PITX3 DNA hypermethylation was significantly associated with the risk of death. These results were validated in a HNSCC cohort from the TCGA Research Network. Furthermore, hypermethylation correlated inversely with PITX3 mRNA expression in the TCGA cohort. Although these findings lead to the conclusion that hypermethylation is associated with silencing of the PITX3 gene, the transcriptional relevance remains unclear. Hypomethylation may result in transcription of the gene; however, the role of PITX3 in tumorigenesis has not been described. One possible mechanism could be the co-transcription of other genes on chromosome 10q such as suppressor of fused homolog (SUFU), which acts as a negative regulator of the hedgehog signaling pathway. Combined loss of SUFU and p53 results in the development of medulloblastomas and rhabdomyosarcoma in mice [40]. Hedgehog signaling may also play a role in HNSCC tumorigenesis. Hence, the transcription of a negative regulator could result in a reduced tumor growth [41]. It has previously been shown that HPV infection may result in alteration of the DNA methylome. Therefore, HPV-mediated epigenetic alterations may account for the hypermethylation in HPVpositive tumors described in the present study [42,43]. However, SUFU and PITX3 are not located on the immediately neighboring regions of 10q24. It is therefore unclear whether methylation of PITX3 could have any influence on SUFU transcription. In a rat model for prostate cancer development following exposure to endocrine-disrupting chemicals, PITX3 was found to be one of several hypomethylated and therefore expressed genes [44]. While this model cannot serve as a model for HNSCC tumorigenesis, it is an interesting finding and possibly allows for the implication of PITX3 alteration being an early event in cancer development. This would be in line with the results of Holmes et al., who were able to show that PITX3 methylation is a strong prognostic marker for biochemical recurrence in localized prostate cancer [22].
HNSCC display a high genomic instability with a mean of 141 copy number alterations per tumor, including amplification of 10q24 [45,46]. Since amplification has been associated with hypermethylation, this might provide an explanation for the observed methylation differences [47]. Even though the biological function remains unclear for now, PITX3 DNA methylation status emerges as a promising biomarker particularly for patients with HPV-negative tumors.
In brief, this is the first study to show that the methylation status of PITX3 is an independent prognostic factor for overall survival in patients with HNSCC. These findings warrant further investigation in a prospective study setting.

Funding
This work was funded by the University Hospital Bonn, Germany.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article or are available from the corresponding author on reasonable request.
Authors' contributions VS and DD analyzed the data, drafted the manuscript, and conceived and coordinated the study. FB, GK, DP, and AS participated in the design of the study and its supervision and revised the manuscript. HG, DG, FD, and AF provided and characterized the sample material. HG revised the manuscript. JD processed the TCGA data. EEH performed the real-time PCR and the DNA preparations and participated in the data analysis. All authors read and approved the final version of the manuscript.

Competing interests
Dimo Dietrich is a consultant for AJ Innuscreen GmbH (Berlin, Germany) and receives royalties from product sales. Dimo Dietrich is a consultant and receives or received compensation from Therawis GmbH (Munich, Germany). Therawis GmbH aims to commercialize the methylation biomarker PITX2. The other authors report to have no conflict of interest regarding the topic of the article.

Consent for publication
Not applicable.
Ethics approval and consent to participate This study was approved by the Institutional Review Board (IRB) at the University Hospital of Bonn. The review board waived the need for written informed consent. All experiments were conducted in accordance with the Helsinki Declaration of 1975.